Cargando…

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale

INTRODUCTION: Protection from lethal ventricular arrhythmias leading to sudden cardiac death is one of the most important problems after myocardial infarction. Cardiac sympathetic hyperactivity is related to poor prognosis and fatal arrhythmias and can be non-invasively assessed with heart rate vari...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubota, Yoshiaki, Yamamoto, Takeshi, Tara, Shuhei, Tokita, Yukichi, Yodogawa, Kenji, Iwasaki, Yuki, Takano, Hitoshi, Tsukada, Yayoi, Asai, Kuniya, Miyamoto, Masaaki, Miyauchi, Yasushi, Kodani, Eitaro, Sato, Naoki, Tanabe, Jun, Shimizu, Wataru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167287/ https://www.ncbi.nlm.nih.gov/pubmed/30097993 http://dx.doi.org/10.1007/s13300-018-0480-7

Ejemplares similares

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
por: Shimizu, Wataru, et al.
Publicado: (2020)

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
por: Mozawa, Kosuke, et al.
Publicado: (2021)

Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
por: Hoshika, Yu, et al.
Publicado: (2021)

Status of Medical Care and Management Requirements of Elderly Patients With Heart Failure in a Comprehensive Community Health System　― Survey of General Practitioners’ Views ―
por: Tsukada, Yayoi Tetsuou, et al.
Publicado: (2021)

Validation of wearable textile electrodes for ECG monitoring
por: Tsukada, Yayoi Tetsuou, et al.
Publicado: (2019)

Predictive Factors for Decreasing Left Ventricular Ejection Fraction and Progression to the Dilated Phase of Hypertrophic Cardiomyopathy
por: Ishihara, Kakeru, et al.
Publicado: (2023)

Plaque Characteristics in Coronary Artery Disease Patients with Impaired Glucose Tolerance
por: Suzuki, Keishi, et al.
Publicado: (2016)

Feasibility and safety of CT‐aided pericardiocentesis from a subxiphoid anterior approach by using fluoroscopy in patients with chronic pericardial effusions
por: Iwasaki, Yu‐Ki, et al.
Publicado: (2022)

Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease
por: Kubota, Yoshiaki, et al.
Publicado: (2015)

Utility of fractional excretion of urea nitrogen in heart failure patients with chronic kidney disease
por: Watanabe, Yukihiro, et al.
Publicado: (2023)

Clinical features and long-term prognosis of patients with congestive heart failure taking tolvaptan: a comparison of patients with preserved and reduced left ventricular ejection fraction
por: Seki, Toshiki, et al.
Publicado: (2021)

COPD advances in left ventricular diastolic dysfunction
por: Kubota, Yoshiaki, et al.
Publicado: (2016)

Effect of Empagliflozin in Preventing Progression of Renal Dysfunction in Diabetic Patients With Compensated Heart Failure　― Reply ―
por: Shirakabe, Akihiro, et al.
Publicado: (2021)

Relationship of maximum walking speed with peak oxygen uptake and anaerobic threshold in male patients with heart failure
por: Koen, Masahiro, et al.
Publicado: (2023)

Cardiogenic cerebral embolism due to sinus arrest associated with coronary intervention for the right coronary artery: A case report
por: Seki, Toshiki, et al.
Publicado: (2021)

External Validation of the Kumamoto Criteria in Transthyretin Amyloid Cardiomyopathy Screening　― A Retrospective Cohort Study ―
por: Watanabe, Yukihiro, et al.
Publicado: (2022)

Empagliflozin Administration Can Decrease the Dose of Loop Diuretics and Prevent the Exacerbation of Renal Tubular Injury in Patients With Compensated Heart Failure Complicated by Diabetes
por: Shirakabe, Akihiro, et al.
Publicado: (2020)

Adjunctive Catheter-Directed Thrombolysis during Primary PCI for ST-Segment Elevation Myocardial Infarction with High Thrombus Burden
por: Noma, Satsuki, et al.
Publicado: (2022)

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
por: Liu, Yihai, et al.
Publicado: (2021)

Intracoronary air embolism with Brugada-type electrocardiographic change after transbronchial lung biopsy
por: Ishihara, Kakeru, et al.
Publicado: (2020)

Myocardial ultrastructure can augment genetic testing for sporadic dilated cardiomyopathy with initial heart failure
por: Saito, Tsunenori, et al.
Publicado: (2021)

Therapeutic options for the treatment of venous thromboembolism in case of warfarin intolerance: Effects of novel oral anticoagulants
por: Kodani, Eitaro
Publicado: (2013)

Enlarged right atrium predicts pacemaker implantation after atrial fibrillation ablation in patients with tachycardia-bradycardia syndrome()
por: Arai, Toshiki, et al.
Publicado: (2023)

Are angiographic culprit lesions true? Disagreement between angiographic and optical coherence tomographic detection
por: Kurihara, Osamu, et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on ST-elevation Myocardial Infarction from a Single-center Experience in Tokyo
por: Watanabe, Yukihiro, et al.
Publicado: (2021)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
por: Liu, Yihai, et al.
Publicado: (2021)

Bisoprolol transdermal patch for perioperative care of non-cardiac surgery in patients with hypertrophic obstructive cardiomyopathy
por: Imori, Yoichi, et al.
Publicado: (2019)

Atrial fibrillation and stroke prevention: state of the art—epidemiology and pathophysiology: new risk factors, concepts and controversies
por: Kodani, Eitaro, et al.
Publicado: (2020)

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
por: Breder, Ikaro, et al.
Publicado: (2020)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Total activation mapping in a patient with an epicardial accessory pathway
por: Fujimoto, Yuhi, et al.
Publicado: (2022)

Correction to: Perioperative coronary artery spasms in patients undergoing catheter ablation of atrial fibrillation
por: Hachisuka, Masato, et al.
Publicado: (2022)

Perioperative coronary artery spasms in patients undergoing catheter ablation of atrial fibrillation
por: Hachisuka, Masato, et al.
Publicado: (2021)

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design
por: Fujiki, Shinya, et al.
Publicado: (2020)

Esophageal pressure monitoring for airway management during catheter ablation of atrial fibrillation
por: Iwasaki, Yu-ki, et al.
Publicado: (2021)

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Evaluation of myocardial glucose metabolism in hypertrophic cardiomyopathy using (18)F-fluorodeoxyglucose positron emission tomography
por: Aoyama, Rie, et al.
Publicado: (2017)

Empagliflozin Suppresses the Differentiation/Maturation of Human Epicardial Preadipocytes and Improves Paracrine Secretome Profile
por: Takano, Masayuki, et al.
Publicado: (2023)

Anemia and atrial fibrillation as independent risk factors for new-onset chronic kidney disease: the TAMA-MED Project—CKD and AF
por: Kaneko, Tomohiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mr8o8e1rsb1t0hcb0r8o0jobdd